Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Estimate, With the Contribution of Optimized MRI, the Prevalence of Neurological and Neurovascular Manifestations on Imaging in the Event of SARS-CoV-2
Interventions
OTHER

MRI

"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* \+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"

Trial Locations (1)

75019

Fondation A De Rothschild, Paris

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT04448054 - Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas | Biotech Hunter | Biotech Hunter